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Mutation Significantly Destabilizes the Protein Leading to
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Here we investigate the effects of a myopathy-causing muta-
tion in B-crystallin, Q151X, upon its structure and function.
Thismutation removes the C-terminal domain ofB-crystallin,
which is expected to compromise both its oligomerization and
chaperone activity.Wecompared this to twootherB-crystallin
mutants (450delA, 464delCT) and also to a series of C-terminal
truncations (E164X, E165X, K174X, and A171X). We find that
the effects of the Q151Xmutation were not always as predicted.
Specifically, we have found that although the Q151X mutation
decreased oligomerization of B-crystallin and even increased
some chaperone activities, it also significantly destabilized
B-crystallin causing it to self-aggregate. This conclusion was
supported by our analyses of both the other disease-causing
mutants and the series of C-terminal truncation constructs of
B-crystallin. The 450delA and 464delCT mutants could only
be refolded and assayed as a complex with wild type B-crystal-
lin, which was not the case for Q151XB-crystallin. From these
studies, we conclude that all three disease-causing mutations
(450delA, 464delCT, and Q151X) in the C-terminal extension
destabilizeB-crystallin and increase its tendency to self-aggre-
gate.We propose that it is this, rather than a catastrophic loss of
chaperone activity,which is amajor factor in thedevelopment of
the reported diseases for the three disease-causing mutations
studied here. In support of this hypothesis, we show that Q151X
B-crystallin is found mainly in the insoluble fraction of cell
extracts from transient transfected cells, due to the formation of
cytoplasmic aggregates.
The crystallins were first identified as the major proteins of
the eye lens and their subsequent classification into -, -, and
-crystallins (1) allowed different functional properties to be
assigned to the - and -crystallin groups (2). The -crystal-
lins are two distinct proteins derived from two separate genes,
A- and B-crystallin (2). Whereas A-crystallin is almost
entirely lens specific (3), B-crystallin is expressed widely in
other tissues, most notably astrocytes (4) andmuscle (5). In the
early 1980s, pioneering work fromKlemenz and co-workers (6)
and Horwitz (7) laboratories established that B-crystallin was
a protein chaperone and a member of the small heat shock
protein (sHSP)2 family, that is now known to comprise 10 dif-
ferent human proteins (8).
When the first mutation (R120G) in B-crystallin was
reported, it was found to cause both cataract and desmin-re-
lated myopathy in the affected patients (9). Characteristic his-
topathological aggregates of the muscle intermediate filament
protein desmin were observed (9), strongly suggesting that
there is an important functional interaction between interme-
diate filaments and B-crystallin. Subsequent analyses showed
that the R120GB-crystallinmutation induced increased bind-
ing for desmin intermediate filaments (10), providing an expla-
nation for the formation of the desmin aggregates in the mus-
cles of the affected individuals. Coincidentally, mutations in
desmin also induced filament aggregation (11, 12) and these
aggregates also contained B-crystallin (12). Collectively, these
data suggest that one of the functions of B-crystallin is to
chaperone intermediate filaments and their networks in cells
(10, 13, 14).
Subsequently, three other mutations in the C-terminal
extensionwere reported forB-crystallin, but in contrast to the
R120G mutation, none caused both cataract and myopathy.
The first of these was the 450delA mutation that is associated
only with cataract and resulted in a 184-residue product where
the coding sequence of the C-terminal extension was altered
from residue 150 onwards (15). This region is distal to the
-strand 9 and proximal to the conserved hydrophobic IX(I/V)
motif (16) that forms part of-strand 10 in the crystal structure
of the archaeal HSP16.5 (17). Two other mutations were then
reported (Q151X and 464delCT) that cause myopathy and not
cataract (18) that either truncated (Q151X) or substituted the
C-terminal extension from residue 155 (464delCT). The fact
that all three mutations delete a known substrate interaction
site (157–164) (19) and a region important in the oligomeriza-
tion of B-crystallin itself (155–166) (20) support the hypothe-
sis that this region in B-crystallin is important to both the
structure and function of the protein. Very recently, a C-termi-
nal point mutation (R157H) (21) was reported, lending further
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support to this conclusion. Thus far, the effect of such extensive
deletions (Q151X) combined with altered C-terminal
sequences (450delA and 464CT) upon B-crystallin structure
and function have not been investigated.
In other sHSPs, the C-terminal domain has been shown to be
very important to both oligomerization and chaperone func-
tion and therefore the expectation is that the C-terminal exten-
sionmutations would similarly affect B-crystallin. Removal of
the 17 most C-terminal residues of A-crystallin reduced its
chaperone activity and induced the formation of larger oli-
gomers (22). In two crystal structures of sHSPs (HSP16.5 (17)
and HSP16.9 (23)), the C-terminal extension makes contact
with a hydrophobic patch on neighboring protein subunits,
strengthening the dimer-dimer interaction in the oligomer
(23). The sequence between -strands 9 and 10 of the C-termi-
nal extension contains a hinge that likely contributes to the size
polydispersity of the different sHSPs by allowing packing geom-
etries to vary while maintaining common interaction surfaces
(23). Some naturally occurring sHSPs lack a C-terminal exten-
sion and in such cases the oligomerization is restricted, as seen
for Tsp36 from the tapeworm Taenia saginata, which forms
dimers and tetramers, but is functional as a chaperone (24).
Likewise, removal of the short C-terminal extension from
Methanococcus janaschii HSP16.5 resulted in reduced oli-
gomerization, but the retention of chaperone activity (25). This
is quite contrary to the closely related lens chaperone A-crys-
tallin that naturally co-oligomerizes with B-crystallin in the
lens. Stepwise removal of C-terminal sequences from A-crys-
tallin, including the REEKmotif, not only reduced oligomeriza-
tion, but also resulted in the sequential loss of chaperone activ-
ity (26), despite the fact that the IX(I/V) motif was retained in
themutants investigated.Mutations of lysine and glutamic acid
residues in the C-terminal extension can improve chaperone
activity against amyloid fibril formation providing a potential
application ofB-crystallin in the treatment of amyloid-related
diseases (27). In B-crystallin, there has not been any system-
atic analysis of the role of the C-terminal extension and there-
fore no potential explanation of whether the three mutations
(450delA, Q151X, and 464delCT) cause the various diseases via
the loss of chaperone function or perhaps by a different
mechanism.
In this study, we have analyzed the effects of the Q151X,
464delCT, and 450delA upon the oligomerization and chaper-
one activity of B-crystallin. For comparison, we have also
assessed the activity of a series of B-crystallin constructs trun-
cated at residues Lys174, Ala171, Glu165, and Glu164 to sequen-
tially remove important regions of the C-terminal extension
and therefore help us understand the effect of theQ151Xmuta-
tion. With respect to the role of the C-terminal extension in
oligomerization, our data show similar results to those obtained
for A-crystallin (28). Interestingly, the chaperone function of
Q151X is actually increased in some in vitro chaperone assays.
The ability of Q151X B-crystallin to resist self-aggregation is,
however, very greatly diminished, a trend that is further
enhanced by the 464delCT and 450delA mutations, which are
only stable in the presence of wild type B-crystallin. These
data show that like other sHSPs, the C-terminal extension is
important for oligomerization. Its removal increases the tend-
ency of B-crystallin to self-aggregate.
EXPERIMENTAL PROCEDURES
Construction ofB-CrystallinMutants
Primers (Table 1; Sigma Genosys, UK) were designed based
on the mRNA sequence for wild type human B-crystallin
(DDBJ/EMBL/GenBank entry NM_001885) and were used to
TABLE 1
Oligonucleotide primer sequence details used for introduction of the B-crystallin mutations
The unique restriction enzyme sites incorporated into the primer design are highlighted in bold text. Q151X and E165X were introduced using site-directed mutagenesis
(SDM) requiring complementary forward (5-3) and reverse (3-5) primers. The 464delCT, K174X, A171X, and E164X mutant mRNA were amplified using a forward
primer overlapping the pET23d insertion site and the 5 end of the template wild typeB-crystallin. Reverse primers were complementary to the 3 end of the template wild
typeB-crystallin and incorporated themutation and unique restriction sites to assist screening, using the available software (DNA_Analysis_Frame). A suitable restriction
enzyme site was not available for the 464delCT mutation.
Mutant B-crystallin Restriction enzyme site Primer sequence (5-3)
Q151X StuI Forward primer:
gtgaatggaccaaggaaataggcctctggccctgagcgcacc
Reverse primer:
ggtgcgctcagggccagaggcctatttccttggtccattcac
E165X HindIII Forward primer:
attcccatcacccgtgaatagaagcttgctgtcaccgcagccccc
Reverse primer:
gggggctgcggtgacagcaagcttctattcacgggtgatgggaat
464delCT NAa Forward primer:
taccatggacatcgccatccaccacc
Reverse primer:
tcacgggtgatgggaatggtgcgctcggccagagacctgtttcc
K174X SacII Forward primer:
taccatggacatcgccatccaccacc
Reverse primer:
ctagggggccgcggtgacagcaggcttc
A171X SacI Forward primer:
taccatggacatcgccatccaccacc
Reverse primer:
gggcatctatttcttgggagctcaggtgacagcaggcttctc
E164X PstI Forward primer:
taccatggacatcgccatccaccacc
Reverse primer:
cttgggagctgcggtgactgcaggcttctcttaacgggtgatgggaatggt
aNA, not applicable.
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generate the mutants listed, using wild type B-crystallin as a
template for PCR mutagenesis. With the exception of the
Q151X and E165X mutations, the amplified products were
cloned into the vector pGEM-T Easy (Promega). After verifi-
cation of the sequences, the mutant B-crystallin constructs
were subcloned into the NcoI and EcoRI sites of the expression
vector pET23d (Invitrogen). The Q151X and E165Xmutations
were introduced into pET23d by site-directed mutagenesis
(Stratagene) using complementary primers (see Table 1). Con-
structs were sequenced and compared for fidelity to the Gen-
BankTM data base (accession number NM001885).
Protein Expression and Purification ofB-CrystallinMutants
Proteins were recombinantly expressed in Escherichia coli
strain BL21 (pLysS). The wild type B-crystallin, K174X and
A171Xproteinswere prepared essentially as described (29), but
adding polyethyleneimine (final concentration 0.1% (w/v)) to
remove contaminating DNA (10, 30) before purification by ion
exchange chromatography on a Fractogel TMAE column. Peak
fractions were pooled and then dialyzed into 20 mM Tris-HCl,
100 mM NaCl, pH 7.4, in preparation for size exclusion chro-
matography on a Fractogel EMD BioSEC Superformance col-
umn (60 1.6 cm; VWR, UK).
All othermutantB-crystallins formed inclusion bodies, and
were purified essentially as described (31). These were dis-
solved in 10mMTris-HCl, 6Murea, 1mMEDTA, pH8.0, 0.2mM
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and then
purified by ion exchange chromatography (29) on a Fractogel
TMAE column.
Fractions containing B-crystallin were pooled and some-
times concentrated using an Amicon Ultra Centrifugal filter
device 10K MWCO (Millipore, Bedford, MA). Concentrations
of the purified proteins were determined using BCA Protein
Assay reagent kit (Pierce) unless otherwise stated.
Refolding ofB-CrystallinMutants following Inclusion Body
Purification
In the Presence ofWild TypeB-Crystallin
The 450delA, 464delCT, and Q151X were refolded in the
presence of wild typeB-crystallin.Wild typeB-crystallinwas
dialyzed for 16 h at 4 °C into 10 mM Tris-HCl, 6 M urea, 1 mM
EDTA, pH 8.0, 1 mM dithiothreitol. Protein concentration of
the wild type and mutant B-crystallin were determined by
OD280 (extinction coefficients were determined using the
Emboss Pepstats program) and then mixed in a 1:1 ratio.
Diluted Refold Protocol (450delA/Wild Type, Q151X/Wild
Type, E164X, andQ151X)
The protein mixture was diluted to 0.25 mg/ml in 10 mM
Tris-HCl, 6 M urea, 1 mM EDTA, pH 8.0, 1 mM dithiothreitol
followed by an additional 6-fold dilution to 1 M urea in refold
buffer (10 mM Tris-HCl, 5 mM EDTA, 1 mM EGTA, 150 mM
NaCl, pH 7.5) prior to dialysis against the same buffer for 4 h at
16 °C. The dialysate was partially concentrated using Amicon
UltraCentrifugal filter device 10KMWCO(Millipore) and cen-
trifuged for 2 h at 4 °C at 250,000  g in the Beckman Optima
MAX Ultracentrifuge MLA-80 rotor (Beckman Instruments
Inc., Fullerton, CA). The supernatant was further concentrated
to a suitable volume.
Undiluted Refolding Protocol (464delCT/Wild Type, E165X)
The protein mixture was dialyzed into refold buffer for 4 h at
16 °C. The dialysate was centrifuged for 2 h at 4 °C at 250,000
g in the Beckman OptimaMAX Ultracentrifuge MLA-80 rotor
(Beckman Instruments Inc.) and the supernatant concentrated
to give the desired protein concentration.
Characterization ofB-CrystallinMutants
Analytical Size Exclusion Chromatography (SEC)
Purified B-crystallin proteins were analyzed using a Super-
ose 6 column (290  10 mm) at a flow rate of 0.2 ml/min at
room temperature using a Merck-Hitachi Biochromatography
system. The data were analyzed using Chromeleon 6.30 soft-
ware (Sunnyvale, CA).
Mass Spectrometry for MolecularWeight Determination
Purified proteins were loaded onto a MassPREP desalting
cartridge (Waters, Elstree, Herts, UK) to remove buffer con-
taminants. The protein was eluted with 70% (v/v) acetonitrile,
0.5% (v/v) formic acid at 0.2 ml/min and introduced into a
Waters Q-TOF Premier mass spectrometer operating in posi-
tive electrospray mode, with a cone voltage of 40 V. Spectra
were externally calibrated using sodium formate, then cor-
rected for drift using a leucine enkephalin lockspray. Multiply
charged protein ions were deconvoluted using themanufactur-
er-supplied MaxEnt1 software, to determine protein mass.
CD Spectroscopy
Far UV CD spectra of wild type and mutant B-crystallin
were recorded in a cuvette with 0.1-cm path length at room
temperature using a Jasco J-810 spectropolarimeter. Samples
were at a concentration of 0.2–0.3mg/ml, with the exception of
Q151X, assayed at 0.1 mg/ml due to the low yield of soluble
protein. Samples were assayed in 10 mM Tris, 150 mM NaCl, 5
mM EDTA, 1 mM EGTA, pH 7.5. Four data sets were collected
for each sample and averaged, by continuous scanning at 100
nm/min, between wavelengths 190 and 250 nm. The UV CD
spectra were baseline corrected using spectra of the buffer. The
CD spectra were normalized and expressed as molar ellipticity.
Thermal Stability Assay
Absorbance at 360 nm over a temperature gradient of
25–86 °C at 1 °C/min ramp rate was continuously monitored
using the Beckman DU640 spectrophotometer. Samples were
assayed at 0.1 mg/ml.
In Vitro Protein Chaperone Assays
Citrate Synthase—A 200-l volume of citrate synthase from
porcine heart (Sigma) was dialyzed for 16 h at 4 °C against 50
mM Tris-HCl, 2 mM EDTA, pH 8.0, and diluted to 0.49 mg/ml.
The assay mixture contained citrate synthase and B-crystallin
at a 4:1 ratio of substrate:chaperone in 220l. Time-dependant
light scattering was measured at 360 nm every 15 s over 30 min
at 42 °C using a Beckman DU640 spectrophotometer.
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Insulin Assay—A 20-mg aliquot of insulin from bovine pan-
creas (Sigma) was reconstituted in 100 mM NaSO4, 20 mM
NaPO4, pH 6.9 (Insulin buffer), and solubilized by the addition
of 30% (v/v) acetic acid and gentle mixing for 15min. The insu-
lin solution was dialyzed for 16 h at 4 °C against the insulin
buffer and the dialysate was centrifuged for 1 min at 13,000 g
in an Eppendorf bench top centrifuge (5417R; Eppendorf,
Hamburg, Germany). The insulin concentration was deter-
mined from themeasuredOD280 using its extinction coefficient
((A280/5840) 5600mg/ml). Insulin wasmixed with B-crys-
tallin at a 4:1 ratio and the change in light scattering was meas-
ured at 360 nm every 15 s over a period of 15min at 37 °C using
a Beckman DU640 spectrophotometer.
Bis-ANS FluorescenceMeasurements
B-Crystallin variant proteins were incubated in 10mMTris,
150 mM NaCl, 5 mM EDTA, 1 mM EGTA, pH 7.5, at a protein
concentration of 1 M and in the presence of a 10-fold molar
excess of bis-ANS (4,4-dianilino-1,1-binaphthyl-5,5-disulfo-
nic acid, purchased from Invitrogen). Samples were allowed to
equilibrate for 1 h at room temperature prior to the acquisition
of fluorescence spectra on a Varian Cary Eclipse fluorescence
spectrophotometer. The excitationwavelengthwas 410nmand
emissionwas collected between 420 and 700 nmwith excitation
and emission slit widths of 5 nm and a scan speed of 600
nm/min. All spectra are the average of 10 individual scans.
In Vitro Desmin Filament Assembly and Cosedimentation
Assay
In vitro assembly and cosedimentation assays were carried
out essentially as described (10). Recombinant human desmin
was a kind gift from Dr. Ming Der Perng (Durham, UK). Wild
type or mutant B-crystallin was mixed with desmin in low
ionic strength buffer at a 1:1 mass ratio at 0.1 mg/ml. After
filament assembly, samples were separated into pellet and
supernatant fractions by high speed centrifugation (80,000 g
for 30 min at 20 °C in a Beckman TLS-55 rotor (Beckman
Instruments Inc., Fullerton, CA)) as described (10) to pellet
assembled desmin filament and the associated B-crystallin.
To investigate the ability of the threeB-crystallinmutants and
the other C-terminal truncation constructs to prevent fila-
ment-filament interactions in vitro, an additional low-speed
centrifugation assay was used (2500  g for 15 min in a bench
top centrifuge) as described previously (10). The pellet and
supernatant fractions were analyzed by 12% (w/v) SDS-PAGE
(32) and protein bands visualized by Coomassie Blue staining.
The amount of protein in the supernatant and pellet fractions
were analyzed by a luminescent image analyzer (LAS-1000plus;
Fuji Film, Tokyo, Japan) and quantified using the Image Gauge
software (version 4.0; Fuji Film).
Cell Cultures and Transient Transfection Assays
MCF7 cells were maintained as described previously (10).
Wild type and mutant B-crystallin were subcloned into the
mammalian expression vector pcDNA3.1 (Invitrogen) from the
bacterial expression vector pET23d, using XbaI and HindIII.
Transient transfection of these cells was achieved using Gene-
Juice transfection reagent (Novagen) according tomanufactur-
er’s protocol. Cells were allowed to recover for 24 h before proc-
essing for immunofluorescence microscopy, cell fractionation,
and immunoblotting.
Cell Fractionation, SDS-PAGE, and Immunoblotting
Cells grown on 10-cm dishes were washed twice with phos-
phate-buffered saline before being lysed with 1ml of extraction
buffer (phosphate-buffered saline, 0.5% (v/v) Triton X-100) by
repeatedly passing through a 25-gauge needle. Following incu-
bation on ice for 15 min, the lysates were clarified by centrifu-
gation 18,000 g for 10 min at 4 °C. The resulting supernatant
and pellet fractions were solubilized in equal volumes of Lae-
mmli sample buffer before SDS-PAGE and immunoblotting
analysis as described (10). Membranes were probed with a
panel of purified mouse monoclonal anti-B-crystallin 2D2B6
and monoclonal anti-HSP27 antibody, ER-D5, as described
(10). Antibody labeling was detected by enhanced chemilumi-
nescence using a luminescent image analyzer (LAS-1000plus;
Fuji Photo Film (UK), London, United Kingdom).
ImmunofluorescenceMicroscopy
Cells were processed as described previously (10). The pri-
mary antibodies used in this study were rabbit polyclonal anti-
B-crystallin, a synthetic peptide corresponding to human
B-crystallin residues 1–10 (MDIAIHHPWI) conjugated to
hemocyanin (1:200; Chemicon Ab1546) and monoclonal
mouse anti-keratin LE41 (1:1; CRUK). Samples were analyzed
using an Axioplan fluorescence microscope (Carl Zeiss, Jena,
Germany). Images were obtained using a confocal Axiovert
200M microscope and LSM 510 META software (both Zeiss,
Germany). Optical sections were set to1.0 m. Images were
processed and prepared for figures using Adobe Photoshop 8.0
(Adobe Systems). Quantitation of theB-crystallin phenotypes
was by visual assessment of the cells.
RESULTS
Expression and Purification of the C-terminal Extension
B-Crystallin Mutants—An overview of the C-terminal exten-
sion mutants in comparison to wild type B-crystallin is pre-
sented (Fig. 1A). It shows the relationship of the various muta-
tions and truncations to the structural features of the
C-terminal extension and also summarizes the consequences of
the two frameshift mutations, 450delA and 464delCT, that
cause inherited cataract (15) and myofibrillar myopathy (18),
respectively. In addition to the three disease-causingmutations
(Q151X, 450delA, and 464delCT), a series of C-terminal exten-
sion truncation constructs were also expressed and purified
(Fig. 1B). All the mutants except A171X and K174X were puri-
fied from inclusion bodies. The predicted mass of each of the
expressed proteins was confirmed bymass spectrometry meas-
urements (Fig. 1C). Whereas Q151X, E164X, and E165X could
be refolded successfully without the addition of wild type
B-crystallin, both 450delA and 464delCT could only be
refolded in its presence.When refoldedwith an equimolar ratio
of B-crystallin, 7% of 450delA and 10% of 464delCT
remained soluble (Fig. 1D). Although Q151X B-crystallin
could be refolded in the absence of wild type B-crystallin, the
yield could be increased some 7-foldwhen thewild type protein
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was included. These data show the disease-causing mutations
seriously affect the solubility of B-crystallin.
The K174X construct removes the two most C-terminal
lysine residues and would be expected to retain the secondary
structural characteristics and oligomerization characteristics of
B-crystallin (33). The electrophoretic mobility of this K174X
mutant was increased relative to the wild type B-crystallin
(Fig. 1B) and is in agreement with previous observations for
C-terminal-deleted forms of B-crystallin (34–37). Removal of
the 5 most C-terminal residues generated the A171X mutant
and is equivalent to the truncated form of B-crystallin found
in normal rat lenses (38), bovine lenses (39), and in ratmodels of
diabetic cataracts (40). Another C-terminal-truncated form of
B-crystallin (E164X) has 12 residues removed from the C ter-
minus and this has been detected in normal rat lenses (41). This
truncation deletes the pair of glutamic acid residues at positions
164 and 165 that are part of the REEK motif in A-crystallin
that have been shown to be important in oligomerization (26).
It is also equivalent to the 10-residue C-terminal-truncated
form of A-crystallin (40).
Truncation of the C-terminal Extension Reduces B-Crystal-
lin Oligomerization—Wild type B-crystallin formed oli-
gomers that were equivalent to 564 kDa, as calculated from the
size exclusion chromatography data, agreeing with previously
published data (42). The oligomer population was consistent
between different preparations as shown by dynamic light scat-
tering (supplementary data Fig. S1). The sequential truncation
of the C-terminal extension of B-crystallin produces a steady
decrease in oligomer size (Fig. 2A).
The shortest construct Q151X
B-crystallin produces a peak with
very significantly increased elution
volume (Fig. 2B) and represents the
most dramatic reduction in oli-
gomerization observed for all the
constructs studied. This effect on
Q151X oligomerization is obvious
when the negative stained electron
micrographs of wild type and
Q151X B-crystallin are compared
(Fig. 2, C and D, respectively).
Notice the absence of particles in
the Q151X sample (Fig. 2D) relative
to the wild type (Fig. 2C).
Deletion of the two C-terminal
lysines (K174X) did not alter signifi-
cantly the oligomerization of
B-crystallin, as previously reported
(33). Removal of 5 C-terminal resi-
dues, however, reduced the apparent
size of the main peak, as did the
removal of both 11 (E165X) and 12
(E164X) residues. In the case of the
latter twotruncationmutants, there is
evidence of increased polydispersity
as indicated by the very noticeable
shoulder on the main peak for the
E165X construct and the presence of
an additional peak at the void volumeof the column for theE164X
construct. The elution volume of themain peak is increased, sug-
gestive of reducedmean size for B-crystallin oligomers. These
data suggest that residues Glu164-Glu165 also contribute to
B-crystallin oligomerization.
The two frameshift mutants 450delA and 464delCT
remained insoluble unless they were refolded in the presence of
wild type B-crystallin. As seen from the elution profiles in Fig.
2A, the presence of these mutant proteins decreased the oli-
gomer size of the wild type B-crystallin. SDS-PAGE analysis
(Fig. 1B) revealed that the wild type B-crystallin is present in
excess compared with 450delA B-crystallin, yet this excess
was not sufficient to retain the elution characteristics of the
wild type protein. In fact, this proved to be the maximum ratio
compatible with protein solubility for the 450delA-wild type
B-crystallin complex and is in stark contrast to 464delCT
B-crystallin, where a 1:1 mixture with wild type B-crystallin
was entirely soluble. The presence of the 450delA B-crystallin
also increased the polydispersity of the main peak, as seen by
the shoulder and the additional small peak with a predicted
molecular weight equivalent to B-crystallin dimers.
The 450delA mutation introduces a unique 33-residue
polypeptide completely unrelated to the C-terminal extension
of wild type B-crystallin (Fig. 1A) and quite clearly this frame-
shift sequence has a significant effect upon the oligomerization
of B-crystallin. It is, however, the Q151X mutation that has
the most dramatic effect, with the complete removal of the
single peak equivalent to the 564-kDa oligomer and the appear-
FIGURE 1. Details of the B-crystallin mutants and their characterization by SDS-PAGE. Structural align-
ment of the C-terminal extensions of B-crystallin mutants (A) includes the C-terminal extension from residue
149 (24), and -sheets and the IX(I/V) motif are indicated as black boxes. The 7 sequence spans residues
118–123 (FHRKYR), 8 sequence spans residues 134–138 (TSSLS), and 9 sequence spans residues 142–148
(VLTVNGP). The highly conserved IX(I/V) motif includes residues 159–161 (IPI). The C-terminal extension con-
sists of residues 149–175 (RKQVSGPERTIPITREEKPAVTAAPKK). B, characterization of the bacterially expressed
and purifiedmutants used in this study by SDS-PAGE. The 450delA (arrow) and 464delCT (arrowhead) mutants
could not be produced as individual soluble proteins and therefore were refolded in the presence of wild type
B-crystallin. Molecular weight markers (track M) are indicated (F) in order of increasing relative mobility (40,
33, 24, and 17 kDa). The relative molecular weights of the wild type and mutant B-crystallins (C) were con-
firmed by mass spectrometry and compared with values calculated from the amino acid sequences using the
Emboss Pepstats program.D, refolding yields forB-crystallin truncation constructs andmutants purified from
inclusion bodies.
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ance of a peak with elution characteristics predicted to be
equivalent to a monomer. Non-denaturing gel electrophoresis
also confirmed that the Q151X mutation dramatically altered
its electrophoretic mobility under non-denaturing conditions
in line with significantly altered oligomerization (supplemen-
tary data Fig. 2).
Effect of the C-terminalMutations upon the Secondary Struc-
ture and Oligomerization of B-Crystallin—CD spectroscopy
of wild type B-crystallin showed a single, broad minima,
between 208 and 217 nm, indicative of a protein rich in  sheet
(Fig. 3), which is consistent with previously reported data (42–
46). The Q151X mutation had the most significant effect upon
the far UV CD characteristics of B-crystallin (Fig. 3), due to a
very significant red shift of the minima to 217 nm and a50%
reduction in magnitude, suggestive of a significant loss of sec-
ondary structure. Similar shift patterns have been seen for
C-terminal truncation mutants of A-crystallin (26). A 1:1
molarmixture of Q151Xwith B-crystallin wild type produced
a spectrum that was clearly biased toward the Q151X, indica-
tive of the dominant nature of this mutation.
Of the other mutants studied, the
E164X and E165X mutants were
intermediate in their effects upon
negative ellipticity as compared
with the Q151Xmutant. This inter-
mediate effect is likely associated
with the extent of the C-terminal
truncations of E164X, E165X rela-
tive to Q151X, and suggests a less
significant loss of secondary struc-
ture. Interestingly, the E164X
mutant showed a red shift in the
minimum indicating that the dele-
tion of the second of the two glu-
tamic acid residues in the REEK
motif does introduce a detectable
change in secondary structure. A
recent study showed an R163X
mutant with significantly altered
secondary structure compared with
the wild type (27). The frameshift
mutation, 464delCT, introduced a
small blue shift of the minimum to
208 nm and the appearance of a
shoulder at223 nm, both of which
are indicative of increased helicity.
This increase may be the result of
helix formation by the novel C-ter-
minal sequence. Both the K174X
and A171X truncation mutants and
the 450delA frameshift mutant have
far UV CD spectra very similar to
the wild type B-crystallin.
Loss in Heat Stability of B-Crys-
tallin Correlates with Changes in
Secondary Structure—To probe the
consequences of the altered second-
ary sequence characteristics of the
B-crystallin C-terminal extensionmutants, their heat stability
was determined (Fig. 4). These data show that the two most
unstable mutants are E164X and E165X because both the onset
and optical signal was very significantly increased compared
with wild type B-crystallin for these two mutants. The E164X
mutant began to aggregate at 46 °C, some 30 °C lower than the
wild type protein. The E165Xmutant was notable for the rapid-
ity of aggregation when initiated at 57 °C, whereas the Q151X
mutant was notable in its failure to develop a strong OD360
signal, despite the very significant decrease in stability indicated
by the increased turbidity at 53 °C. This signal reached a maxi-
mumat 55 °C and remained constant until the conclusion of the
assay. The two shorter C-terminal truncations (K174X and
A171X), showed decreased stability, but were themost stable of
the constructs studied.
These data suggest a correlation between altered secondary
structure anddecreased heat stability. This trend is also seen for
the two frameshift mutants (450delA/wild type and 464delCT/
wild type) that were more stable than the three shortest con-
structs, but less stable than either the A171X or K174X trunca-
FIGURE 2. Effect of the Q151Xmutation upon the oligomerization ofB-crystallin. The elution profiles of
the various B-crystallins were determined on a 290 10-mm Superose 6 column (A). The elution character-
istics of the various mutants are plotted relative to those obtained for wild type B-crystallin (wild type), as
highlighted by the vertical line indicating the retention time of the oligomeric complex, which is themajor and
only peak resolved in thewild typeB-crystallin sample. Additionalminor species seen in E164X and 450delA/
wild typearehighlighted.A summaryof the retention times (B) is shown for themajorpeak resolvedduringSEC
of thewild typeB-crystallin andother constructs. The retention timesofminorpeaks are included in the figure
as appropriate. The retention times (S.D.) were calculated from the average of three cycles of SEC. Negative
stained imagesofwild type (C) andQ151XB-crystallin (D)wereobtainedby transmissionelectronmicroscopy
and illustrate the absence of characteristic particles in the Q151X sample, in agreement with the SEC data. Bar,
500 nm.
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tion constructs. These data correlate with more conservative
changes in secondary structure as detected by far UV CD spec-
troscopy for the two frameshift mutants (Fig. 3) and the largely
unchanged spectra for the A171X and K174X mutants.
Effect of C-terminal Extension Mutants upon Exposed
Hydrophobicity—The probe, bis-ANS, has a low fluorescence
quantumyield in aqueous solution, however, this increases dra-
matically upon binding to surface-exposed hydrophobic
regions. As can be seen in Fig. 5, all the B-crystallin mutants
bind more bis-ANS relative to the
wild type B-crystallin, except for
the Q151X mutant, which binds
substantially less. As all the mutants
except Q151X B-crystallin form
oligomers (Fig. 2), we infer from
these data that the increase in
exposed hydrophobic surfaces arise
from changes within their respec-
tive oligomeric structures. The rea-
son why Q151X B-crystallin binds
so little bis-ANS is probably due the
combined effects of decreased oli-
gomerization and loss of secondary
structure.We tested this by examin-
ing the bis-ANS binding properties
of the wild type protein under
mildly denaturing conditions (2 M
guanidinium hydrochloride), which
have been shown previously to eject
B-crystallin from native -crystal-
lin oligomers and to cause a signifi-
cant loss of secondary structure
(47). Indeed the presence of the gua-
nidinium hydrochloride greatly
reduced the bis-ANS binding to
wild type B-crystallin, with the flu-
orescence intensity dropping
almost as low as that obtained for
Q151X B-crystallin alone.
Effect of C-terminal Extension
Mutations upon B-Crystallin
Chaperone Activity—Citrate syn-
thase (Fig. 6A) and insulin (Fig. 6C)
chaperone assays were used to
determine the effects of the
B-crystallin C-terminal extension
mutations. Our expectation was
that the observed chaperone activity
would correlate with the effects of
the mutations on protein secondary
structure and heat stability.We pre-
dicted that E164X, E165X, and
Q151X would exhibit the least
activity in this assay. The chaperone
activity achieved by these mutants
in a citrate synthase aggregation
assay (Fig. 6B) showed that whereas
E164X was indeed the worst of all
the B-crystallin constructs (57% inhibition) none of the
other C-terminal extension constructs performed worse that
the wild type protein (100% inhibition). Indeed, the E165X
(313%)was slightly better than thewild type protein andQ151X
(755%) was one of the best. In fact, the combination of Q151X
andwild typeB-crystallinwas the best chaperone in the citrate
synthase assay (1263% inhibition).
Another surprise from the citrate synthase chaperone assay
was the relative performance of the two frameshift mutants,
FIGURE 3. Circular dichroism of wild typeB-crystallin and the C-terminal extensionmutants. Far UV CD
spectra (205–250 nm) for each proteinwere the average of four spectra. The far UV CD signal was converted to
molar ellipticity expressed as degree/cm2/dmol
1 to normalize for slight differences in molecular mass
between the wild type and the other B-crystallin constructs. The far UV CD spectra of wild type, A171X, and
K174X are similar in shape and magnitude and contained broad minima between 208 and 217 nm. The
450delA/wild type and 464delCT/wild type mixtures show increased negative ellipticity and a shift in minima
to 208 nm. Truncation of the C-terminal extension results in the loss of secondary structure reflected by a
decrease in negative ellipticity and a shift inwavelengthminima (E164X, E165X, Q151X, andQ151X/wild type),
with the most dramatic effects seen for Q151X.
FIGURE 4. Thermal stability of wild type and C-terminal extensionmutants ofB-crystallin. The effect of
theC-terminal extensionmutations on theheat-induced aggregationofB-crystallinwasmeasured at 360nm
over the temperature range 25–86 °C. The temperature was increased at a 1 °C/min over 1 h. Wild type and
mutant B-crystallins were assayed at 0.1 mg/ml. Notice the significantly reduced stability of the E164X,
Q151X, and E165X B-crystallin mutants.
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450delA and 464delCT, both of which performed better in
combination with wild type B-crystallin than the wild type
B-crystallin alone (625 and 216% inhibition, respectively).
These data show that the disease-causing mutations in
B-crystallin (Q151X, 450delA, and 464delCT) all retain signif-
icant chaperone activity, surpassing the potential of the wild
type protein alone for this client protein in this particular chap-
erone assay.
In contrast to the results with citrate synthase, all the C-ter-
minal extension mutants performed worse than the wild type
B-crystallin in the insulin-based chaperone assay (Fig. 6C). In
this assay, the three most heat-sensitive B-crystallin mutants,
E164X, E165X, and Q151X, increased protein aggregation
compared with wild type B-crystallin (138, 8, and 45%
inhibition, respectively (Fig. 6D)). An equimolar mixture of
Q151X and wild type B-crystallin (47% inhibition) retained
significant chaperone activity of Q151X, but it was still one of
the poorer chaperones in this assay. The K174X (93%) and
A171X (93%) mutants had chaperone activities that most
closely resembled the wild type B-crystallin (100%) and even
the two frameshift mutants, 450delA and 464delCT, in their
respective combinations with wild type B-crystallin, still pos-
sessed credible activities (68 and 78% inhibition, respectively).
Ability of the Disease-causing B-Crystallin Mutants to
Inhibit Desmin Filament Aggregation—One of the characteris-
tic histopathological features of the human myopathies caused
by some of the mutations in B-crystallin under investigation
in this study is the presence of aggregates of desmin filaments
(9, 12). It was therefore decided to analyze the ability of the
B-crystallinmutants in this study to prevent desmin filament-
filament associations (Fig. 7), using an assay developed to inves-
tigate the cell biological effects of the R120G mutation in
B-crystallin (10).
The assay takes advantage of the
fact that intermediate filaments
interact with each other in solution
(10, 48) and this can bemeasured by
sedimentation assay. The presence
of a mutant protein that interacts
with desmin filaments, for ex-
ample, R120GB-crystallin, activity
encourages more filament-filament
associations and therefore increases
the proportion of pelletable desmin.
Both Q151X and 464delCT B-
crystallin when mixed with wild
type displayed desmin filament
associations similar to wild type
alone, whereas the 450delA/wild
type protein mixture was signifi-
cantly more effective than R120G
B-crystallin in inducing this fila-
ment association, highlighting the
dominant effect of the 450delA
mutation over the wild type
B-crystallin (Fig. 7).
In stark contrast to these results,
the Q151X B-crystallin was the
most effective chaperone of all the disease-causingmutants and
was also better than wild type B-crystallin in reducing the
proportion of pelletable desmin (Fig. 7A). Most of the Q151X
mutant co-sedimented with desmin in the pellet fraction (cf.
Fig. 7, B and C). Mixing Q151X with wild type B-crystallin in
an equimolar ratio reduced this binding to desmin filaments (cf.
Fig. 7, B and C) and restored the levels of pelletable desmin to
those obtained in the presence of wild type B-crystallin (Fig.
7A). In contrast, the 450delAmutant was clearly dominant over
thewild typeB-crystallin as therewas not only increased bind-
ing to the filaments (cf. Fig. 7, B and C), but also a significant
increase in the proportion of pelletable desmin (Fig. 7A). We
interpret these data to indicate that the increased binding of
450delA B-crystallin induces more filament-filament interac-
tions resulting inmore desmin in the pellet. Interestingly all the
mutant B-crystallins exhibited elevated binding to desmin fil-
aments (Fig. 7C), but under these assay conditions (0.1 mg/ml
desmin at 37 °C), the Q151X and 450delA B-crystallin had
opposite effects upon the promotion of filament-filament
interactions.
To show that the effects ofQ151XB-crystallinwere not due
to an inhibition of desmin filament assembly per se, negatively
stained samples were analyzed by electronmicroscopy (Fig. 7E)
and the presence of abundant 10-nm filaments confirmed.
When comparedwith desmin assembled in the presence ofwild
type B-crystallin (Fig. 7D), the absence of B-crystallin parti-
cles in the Q151X containing sample was also immediately
apparent, confirming independently the data in Fig. 2,A andD.
Cytoplasmic Aggregate Formation of Selected B-Crystallin
Mutants in MCF7 Cells—The in vitro assays show that the
Q151X mutant increased some chaperone activities, but also
significantly destabilized the protein causing it to aggregate.
We then decided to investigate the behavior ofQ151XB-crys-
FIGURE5.Bis-ANSfluorescencebindingpropertiesofB-crystallinmutants.Theeffectof theC-terminalmuta-
tions upon the relative exposed hydrophobicity was performed using bis-ANS to bind to surface-exposed hydro-
phobic regions on themutant and wild type B-crystallin. Each protein was analyzed at 1M in the presence of a
10-fold molar excess of bis-ANS. The excitation wavelength was 410 nm and emission spectra were collected
between 420 and 700nm. All spectra are the average of 10 individual scans. The resulting exposedhydrophobicity
is increased for all mutants relative to thewild typeB-crystallin, with the exception of theQ151Xmutant.
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tallin when transiently transfected into tissue culture cells (Fig.
8), using MCF7 cells as established in previous studies investi-
gating desmin (49) and B-crystallin (10) mutations. MCF7
cells have high endogenous levels of HSP27, a small heat shock
protein chaperone that is known to form heterogeneous oli-
gomers with B-crystallin (50). The cell line also has little or no
endogenousB-crystallin (10, 14), thus avoiding the need to tag
the protein for subsequent detection. Cells expressingwild type
B-crystallin (Fig. 8A, green channel), showed a homogeneous
cytoplasmic distribution. In contrast, cells expressing the
Q151X mutant B-crystallin were obvious by the presence of
cytoplasmic aggregates that were immunopositive for B-crys-
tallin (Fig. 8B). A similar result was also obtained for two other
B-crystallin constructs, the mutant 464delCT and the C-ter-
minal-truncated B-crystallin E164X (Fig. 8, C and D). Our
previous data (Figs. 2 and 4) suggest that like Q151X, both were
destabilized and prone to self-aggregation and the fact that
both also form cytoplasmic aggregates supports this conclu-
sion.Our data also complement a paper published as ourmanu-
script was being reviewed, which found that both Q151X and
464delCT B-crystallin formed aggregates in transfected cells
(51). To provide an assessment of the solubility of the different
B-crystallin constructs in populations of transiently trans-
fectedMCF7 cells, cell extracts were produced and fractionated
into supernatant and pellet fractions by centrifugation prior to
analysis by SDS-PAGE and immunoblotting with antibodies to
HSP27 and B-crystallin (Fig. 8E). Transfected wild type
B-crystallin was found almost entirely in the soluble fraction
(Fig. 8E, lane 1). Transfected Q151X, 464delCT, and E164X,
however, were detected almost entirely in the pellet fractions
(Fig. 8E, lanes 4, 6, and 8, respectively) with only a small pro-
portion left in the supernatant fractions (Fig. 8E, lanes 3, 5, and
7, respectively). The endogenous HSP27 was unable to prevent
the formation of aggregates by the mutant B-crystallins and
the presence of these aggregates did not cause a significant shift
in the solubility of the endogenousHSP27 to the pellet fraction.
These data support our hypothesis that the loss of the C-termi-
nal domain, as occurs in the Q151X mutation, dramatically
FIGURE 6.Aggregationof citrate synthase and insulin in thepresence ofwild type andmutantB-crystallins. The effect ofwild type andmutantB-crystallin
on the thermal aggregation of citrate synthase (A and B), over a 30-minperiod at 42 °C, and reduction-induced aggregation of insulin (C andD), over a 15-minperiod
at 37 °CwasmeasuredusingOD360 (OD360). A 4:1molar ratio of substrate:chaperonewas used. The relative inhibition of citrate synthase (B) and insulin (D) aggrega-
tion by the C-terminal extensionmutants was calculated as a percentage of the level of inhibition achieved bywild typeB-crystallin alone (100% inhibition). These
data represented the average (S.D.) of three independent experiments (see supplementary data Figs. S3 and S4 for the complete data sets).
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increases the tendency of B-crystallin to self-aggregate, even
in a cellular environment.
DISCUSSION
Removal of the C-terminal Extension Reduces B-Crystallin
Oligomerization, but Not Chaperone Activity—The consensus
view that has emerged from recent studies on mammalian
sHSPs is that the C-terminal extension is important for oli-
gomerization and chaperone function (19, 22, 26, 28). The
study presented here is the first to investigate the effects of
sequentially truncating this domain (Lys174, Ala171, Glu165, and
Glu164) upon both aspects for B-crystallin. It shows that dele-
tion of the last 5 residues can improve chaperone activity in the
citrate synthase assay without dramatically changing the sec-
FIGURE 7. Sedimentation assay to investigate the prevention of desmin filament aggregation in the presence of various B-crystallins at 37 °C.
A–C shows the % desmin pelleted (A), the % B-crystallin wild type and mutants remaining soluble in the presence of desmin (B), and the % of the total
B-crystallin pelleted in the presence of desmin (C), following low-speed centrifugation (2500 g). These data were calculated from SDS-PAGE data of the
desmin binding assays.D, an example of the data used to calculate these values for wild type, Q151X/wild type, and Q151X B-crystallin. These data illustrate
the ability of the Q151X B-crystallin to prevent desmin filament aggregation. Images obtained by electron microscopy of negatively stained samples of the
assembledfilaments fordesminassembled inthepresenceofwildtype(E) andQ151X(F)B-crystallinareshowntoshowthat theadditionofbothchaperoneshasnot
dramatically altered filamentmorphology or length. Notice the lack of crystallin particles in theQ151X sample. Bar, 100 nm. S, supernatant; P, pellet.
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ondary structure or oligomerization of B-crystallin. Trunca-
tions (E164X, E165X) in the conserved REEK motif (26)
decreased chaperone activity and oligomerization, although
this coincided with more polydispersity for the oligomer as
judged by size exclusion chromatography (Fig. 2). The removal
of theC-terminal extension by theQ151Xmutation produced a
construct with the best chaperone activity profile of all the indi-
vidual protein clients investigated (Figs. 6 and 7) despite the
most significant changes in secondary structure (Fig. 3), bis-
ANS binding (Fig. 5), and altered oligomerization (Fig. 2).
Whereas these results are in broad agreement with the con-
sensus for other mammalian sHSPs, they demonstrate that the
removal of the C-terminal extension from residue 151 prevents
oligomerization (at concentrations less than 0.1 mg/ml), but
not at the expense of chaperone function for B-crystallin.
Indeed the citroconylation of full-length B-crystallin achieves
similar results and together with these data strongly support
the conclusion that oligomerization is not required forB-crys-
tallin chaperone activity (42).
Deletion of the C-terminal Extension by the Q151XMutation
Increases Chaperone Activity for Some Client Proteins—The
somewhat surprising observation is that the Q151X mutation
actually improved chaperone activity for some client proteins
(desmin and citrate synthase), in stark contrast to the effect of
removing a similar region from A-crystallin where chaperone
activity was lost (22, 28).
The C-terminal extension deleted by the Q151X mutation
includes the IX(I/V)motif (16), which is part of-strand 10 (17,
23), that has been shown to be both part of a client protein
binding site (19) and an oligomerization sequence (20) in
B-crystallin. This is removed by all three disease-causing
mutations, including Q151X, but retained in the other trunca-
tion constructs (Fig. 1). Glycine substitutions in the IX(I/V)
motif not only increased oligomerization and polydispersity of
B-crystallin, but also significantly increased chaperone activ-
ity (52). The data we have presented for Q151X B-crystallin
and the other truncation constructs suggest that the client pro-
tein binding site that embraces the IX(I/V) motif (19, 53) is not
only dispensable for activity, but that it could actually inhibit
chaperone function as its removal actually increased activity
(citrate synthase,7.5-fold; desmin,2-fold).
A three-dimensional model of B-crystallin has suggested
that the C-terminal extension potentially acts as a “cap ” on an
important oligomerization and client protein binding site,
namely the 3-8-9 interface (46). This region also interacts
with the4 strand, which is important in sHSP oligomerization
as seen from the crystal structure of HSP16.9 (23), but it is also
critical for chaperone activity (46). In fact reducing B-crystal-
lin to just its -crystallin domain spanning residues 57–157,
which still includes the 3-8-9 surface, retained chaperone
activity, but this construct only formed dimers and could not
oligomerize (54). It is easy to explain these observations and
also our data on the Q151X B-crystallin mutant, in terms of
how the removal of this C-terminal extension cap as proposed
in themodel (46) could allow substrate to bindmore readily and
thus enhance chaperone function while also decreasing oli-
gomer size. The data we have presented here support this
model and also add an interesting dimension. Our data also
suggest that the C-terminal extension actually limits the full
potential of B-crystallin chaperone activity for some client
proteins.
Aggregation of B-Crystallin Encouraged by the Removal of
the C-terminal Extension—The strong tendency of Q151X to
aggregate at protein concentrations greater than 0.1mg/ml and
its very low refolding yield (Fig. 1D), suggests another potential
role played by the C-terminal extension in preventing the
uncontrolled self-aggregation of B-crystallin (55). From the
available sHSP crystal structures (17, 23), the C-terminal exten-
sion is solvent exposed and contributes to the higher order
assembly of the oligomer (23, 56–58). In HSP16.9, the IX(I/V)
motif from one subunit lays in a hydrophobic groove between
4 and 8 strands of the other interacting monomer. Although
B-crystallin has similar structural features, including the con-
FIGURE 8. Decreased solubility and increased aggregation potential of
Q151X B-crystallin is revealed by transient transfection into MCF7
cells. A–D, MCF7 cells transiently transfected with wild type (A), Q151X (B),
464delCT (C), or E164X (D) B-crystallin were fixed at 24 h post-transfection
andprocessed for immunofluorescencemicroscopy. The subcellular distribu-
tion of B-crystallin and keratin were visualized by double labeling with
monoclonal anti-keratin (red channel) and polyclonal anti-B-crystallin anti-
bodies (green channel). A–D are merged images, showing the superimposi-
tionof thegreen, red, andblue (4,6-diamidino-2-phenylindole staining) chan-
nels. Images are individual optical sections acquired using a confocal laser
scanning microscope (Zeiss 510). Cells expressing wild type B-crystallin (A)
showed the expected cytoplasmic distribution of B-crystallin. In contrast,
cells expressingmutantB-crystallin resulted in the formationof cytoplasmic
aggregates of B-crystallin (B–D). Notice that 464delCT aggregates are scat-
tered throughout the cytoplasm, whereas the Q151X and E164X aggregates
locate to the perinuclear region of the cell. Bars, 10 m. Immunoblotting
analysis (E) of B-crystallin transiently transfected in MCF7 cells shows a shift
in solubility for themutantB-crystallins. At 24 hpost-transfection, cellswere
extracted with detergent buffer followed by centrifugation at 18,000 g for
10 min at 4 °C. The resulting supernatant (S) and pellet (P) fractions were
analyzed by SDS-PAGE followed by immunoblotting analysis using anti-HSP
27 (loading control) and B-crystallin antibodies. The blot was developed
using enhanced chemiluminescence. Whereas wild type B-crystallin was
almost entirely soluble (E, lane 1, labeled S), Q151X (lane 4), 464delCT (lane 6),
and E164X (lane 8) were foundmostly in the pellet fractions (labeled P) of cell
extracts. The relative electrophoretic mobility of mutant B-crystallins is
denoted by the arrowhead (‹). Like wild type B-crystallin, HSP27 was also
largely present in the supernatant fractions (E, lanes 2, 4, and 6, labeled P).
These data are representative of three experiments.
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served IX(I/V) motif in its C-terminal extension (Fig. 1A), the
oligomers it forms aremore polydisperse (55, 59, 60) compared
with either HSP16.5 or HSP16.9, suggesting that the precise
detail for the interactions of the C-terminal extension in
B-crystallin will vary, not least due to the different hinge
sequences between -strands 9 and 10 (23). The strong tend-
ency of Q151X B-crystallin to aggregate suggests that the
C-terminal extension actually prevents such potential errant
associations to favor instead oligomerization.
Reduced Protein Stability and Uncontrolled Self-aggregation
Underlies the Molecular Basis of the Q151X, 450delA, and
464delCT Mutations—The loss of the C-terminal extension
due to the Q151X mutation in B-crystallin dramatically
altered the secondary (Fig. 3) and tertiary structure of the pro-
tein (Fig. 2). This mutant was significantly destabilized as seen
from the heat stability assay (Fig. 4) and showed a dramatic
increase in the tendency to self-aggregate in vitro (Fig. 1) and in
vivo (Fig. 8). Only a small proportion of Q151X B-crystallin
(1%, Fig. 1D) remained soluble after refolding. Even in the
presence of equimolar wild type B-crystallin, the mixture had
significantly altered secondary structure (Fig. 2), which affected
B-crystallin oligomerization (Fig. 3) and reduced refold yields
(Fig. 1D). The Q151X mutation was dominant over the wild
type protein in its effects upon heat stability, solubility, and
secondary structure. These data suggest that the strong tend-
ency to self-aggregate as a result of reduced stability is poten-
tially an important factor in disease development.
Our data for both 450delA and 464delCT also suggest that it
is a similar loss in protein stability that causes cataract and
myofibrillar myopathy, respectively. Both mutants can only be
refolded in the presence of wild type B-crystallin and even
then the temperature stabilities of the mixtures are reduced by
some 20 °C comparedwith thewild type protein alone. Both the
450delA and 464delCTmutations introduced novel C-terminal
peptides that have no homology to the existing C-terminal
extension of B-crystallin (Fig. 1A). Both mutations changed
the oligomerization of wild type B-crystallin and neither
mutant/wild type mixture was an effective chaperone in either
the desmin (Fig. 7) or insulin (Fig. 6,C andD) assays. Indeed, the
450delA mutation actively promoted filament-filament inter-
actions for desmin, as reported previously for R120G B-crys-
tallin (10) and, under the assay conditions here, 450delA was
more efficient than R120G in this activity. Therefore the loss of
chaperone activity coupled with sequestration by client pro-
teins could both contribute to the development of disease in the
case of these twomutants.We suggest, however, that the aggre-
gation of B-crystallin is a key feature that offers potential for
gain of function via its amyloidogenic potential (61).
The most difficult observation to explain regarding the
Q151X mutation is its muscle-specific effect, which restricts
the pathology to myofibillar myopathy (18). In fact all three
disease-causing mutations in the C-terminal extension of
B-crystallin (Q151X, 450delA, and 464delCT) are restricted in
their pathology to either the lens (450delA (15)) or muscle
(Q151X, 464delCT; (18)) and yet B-crystallin is very highly
expressed in both tissues (5). This is a familiar trend for
B-crystallin mutations and even the most recently published
mutation, D140N, causes only lens cataract (62). Thus far,
R120G B-crystallin is the only mutation that has produced
both lens and muscle pathologies (9), but this is not to say that
subclinical pathology can be totally excluded for the other
mutations, includingQ151X, as tissue biopsies from apparently
unaffected tissues were not analyzed. Aggregation is a key his-
topathological feature of the Q151X mutation (18) concurring
with our transient transfection and cell fractionation studies
(Fig. 8) and so, this provides a plausible mechanism to support
a potential dominant negative effect of the mutation by inhib-
iting the chaperone function ofwild typeB-crystallin via coag-
gregation with mutant Q151X as implicated from our in vitro
studies (Fig. 1).
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